Investigational drug · Phase 2
KH-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Premature Ejaculation, Dentin Hypersensitivity.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "KH-001"
First trial start
2024
Oct 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KH-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Premature Ejaculation
- Dentin Hypersensitivity
Largest trials
Live from ClinicalTrials.gov: studies naming "KH-001" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin HypersensitivityPivotal-lookingCompleted
HysensBio Co., LtdIndustry
NCT06264453 · 171 participants · Start Mar 19, 2024 · Primary completion Sep 25, 2024
Drug: KH001; Placebo · For: Dentin Hypersensitivity
Sites: Seoul, South Korea
- Phase 2 Study of KH001 in Long-term Relief From Dentin HypersensitivityPivotal-lookingCompleted
HysensBio Co., LtdIndustry
NCT06464939 · 120 participants · Start Oct 8, 2024 · Primary completion Dec 22, 2025
Drug: KH001; Placebo · For: Dentin Hypersensitivity
Sites: Cambridge, Massachusetts · 2 sites in all
Kadence BioIndustry
NCT07868237 · 82 participants · Start Nov 14, 2023 · Primary completion Aug 28, 2025
Drug: KH-001 besylate; KH-001 besylate placebo · For: Healthy Male Volunteers
Sites: Merthyr Tydfil, United Kingdom
HysensBio Co., LtdIndustry
NCT04804514 · 40 participants · Start Jun 14, 2021 · Primary completion Mar 3, 2023
Drug: KH001; Placebo · For: Dentin Sensitivity
Sites: Seoul, South Korea
Kadence BioIndustry
NCT07434271 · 40 participants (planned) · Start Dec 1, 2025 · Primary completion Oct 31, 2026
Drug: KH-001 ODT; Placebo ODT · For: Premature Ejaculation
Sites: Botany, Australia
Seoul National University Dental HospitalAcademic, hospital or other
NCT07751016 · 36 participants (planned) · Start Dec 30, 2026 · Primary completion Jun 30, 2028
Drug: KH001; Placebo · For: Dental Caries
Sites: Seoul, South Korea
Byoung-Moo SeoAcademic, hospital or other
NCT06580678 · 12 participants · Start Nov 6, 2024 · Primary completion May 7, 2025
Drug: KH001; Placebo · For: Dentin Caries
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- KH-001 delays para-chloroamphetamine-induced ejaculation in anaesthetized rat.
Pfeiffer T, Gericke N, Razanakolona M, et al. · J Sex Med 2026
- Serratia marcescens induces apoptosis in Diaphorina citri gut cells via reactive oxygen species-mediated oxidative stress.
Hu W, Zhao C, Zheng R, et al. · Pest Manag Sci 2024
- Evaluating the Biological Potential of Prodigiosin from Serratia Marcescens KH-001 Against Asian Citrus Psyllid.
Hu W, Zheng R, Liao Y, et al. · J Econ Entomol 2021
- Killing Effects of an Isolated Serratia marcescens KH-001 on Diaphorina citri via Lowering the Endosymbiont Numbers.
Hu W, Kuang F, Lu Z, et al. · Front Microbiol 2018
Also in development for Premature Ejaculation
- VV913Phase 21 trial
Vigonvita Life Sciences · Premature Ejaculation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.